首页 > 产品中心 > 抗体 > 药物对照抗体

Anti-Human Siglec-3/CD33 Reference Antibody (Vadastuximab, RUO) (HB185036)

价格:
规格:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
  • 概述

  • 图片

  • 参考文献

  • 产品说明书

概述
货号HB185036
品牌abinScience
描述
Vadastuximab (HB185036) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主Chimeric
同种型IgG1-kappa
表达系统Mammalian cells
克隆类型Monoclonal
经测试应用WB
靶标Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
内毒素水平< 10 EU/mg
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号P20138
状态Liquid
保存溶液 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

稳定性和存储Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名SGN-CD33A, h2H12ec-SGD-1910, h2H12ec-mc-val-ala-SGD-1882, 1436390-63-4
背景

Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343
2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212
3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323
4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872
5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109
6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905
7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955
8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
NoteFor research use only. Not suitable for clinical or therapeutic use.
图片
  • SDS-PAGE

    SDS-PAGE for Research Grade Vadastuximab

  • Bioactivity

    Detects Recombinant Human CD33 Protein, C-His (Cat No.: HB185011) in indirect ELISA.

  • Western blot

    Western blot analysis was performed using anti-CD33 monoclonal antibody at 1ug/mL on various samples.
    Lane 1: recombinant human CD33 (Catalog No: HB185012)
    Lane 2: negative control

参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐